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Abstract
The oncogenic process leading to nasopharyngeal carcinoma (NPC) requires the combination of genetic and epigenetic alterations, latent infec-
tion by the Epstein-Barr virus and local inflammation. A transcriptome analysis of NPC xenografts identified the gene encoding the cellular inhibitor
of apoptosis protein 2 (c-IAP2) among the top fivemost intensely expressed. Consistently, the very high levels of the c-IAP2 protein were detected
in 11 of 13 NPC biopsies. RMT 5265, a structural analog of second mitochondria–derived activator of caspase (SMAC), induced the rapid degra-
dation of c-IAP2 in nasopharyngeal epithelial cells, whether malignant or not, but blocked clonal cell growth in NPC cells only. In short-term ex-
periments, RMT 5265 induced apoptosis in a fraction of NPC cells, and this apoptosis was dramatically enhancedwhen RMT 5265was combined
with Toll-like receptor 3 (TLR3) stimulation. By contrast, the cooperative effect with tumor necrosis factor α was only marginal. The apoptosis
induced by the combination of RMT 5265 and TLR3 stimulation wasmediated by caspase-8 and associatedwith a decrease in the cellular content
of the long isoform of FLICE-like inhibitory protein. Similar caspase-8 activation was obtained when siRNA knockdown of c-IAP2 was combined
with TLR3 stimulation. In conclusion, c-IAP2 has a specific protective function inNPCcells challenged by TLR3 agonists. This protective function is
probably important tomake NPC cells tolerant to their own production of small viral RNAs, which are potential agonists of TLR3. Our data will help
to design a rational use of IAP inhibitors in NPC patients.
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Introduction
Nasopharyngeal carcinoma (NPC) is a malignant tumor arising from
the epithelial lining of the nasopharynx. Consistently associated
with the Epstein-Barr virus (EBV), NPC is the third most frequent
virus-associated malignancy in humans [1,2]. Foci of high incidence
(25 cases per 100,000 individuals per year) are localized in Southeast
Asia, particularly in southern China. There are also large areas of in-
termediate incidence (three to eight cases), for example, Indonesia
and northern Africa [3,4]. The multifactorial pathogenesis of NPC
relies on germ line genetic susceptibility, acquired cellular genetic
and epigenetic alterations, especially under the influence of diet
carcinogens, and EBV infection [1,4,5]. Although most viral genes
are silent in NPC cells, some are consistently expressed including
those encoding the nuclear protein Epstein-Barr nuclear antigen 1,
two membrane proteins latent membrane proteins 1 and 2 (LMP1
and LMP2), and the short untranslated EBV-encoded RNA (EBER)
and EBER2. Of the very large amounts of EBERs produced and
present in the nuclei of NPC cells, some are exported in the cyto-
plasm and possibly in the extracellular space [6].
The treatment of NPC has improved significantly in recent years,
but its prognosis remains serious because of the frequency of distant
metastases—even when the primary tumor is small—and because of
long-term secondary effects of radiotherapy and chemotherapy [7].
The malignant phenotype of NPC cells is supported by a network
of altered biologic pathways resulting from cellular genetic and epi-
genetic alterations combined with latent EBV infection. Local in-
flammation is also suspected to play a major role because of the
consistent presence of a massive lymphoid infiltrate in the primary
tumor and the intense local production of inflammatory cytokines
[8,9]. To better characterize the cellular part in the NPC oncogenic
mechanisms, we took advantage of our cytogenetically characterized
NPC xenografts to carry out a transcriptome analysis that identified
the cellular inhibitor of apoptosis protein 2 (c-IAP2) gene as consis-
tently overexpressed in NPC cells.
The IAPs constitute a family of evolutionarily conserved antiapop-
totic proteins that are thought to contribute to a variety of human
cancers [10,11]. They all contain one to three copies of the charac-
teristic baculovirus IAP repeat (BIR). One IAP protein, X-linked IAP
(XIAP), is produced in large amounts in all cell types and is often
regarded as a housekeeping protein. Another one, survivin, present
in very small amounts in most adult tissues, is overproduced in all
human cancers [12]. Recent studies have highlighted the role of
two other IAPs, c-IAP1 and c-IAP2, as ubiquitin ligases and regula-
tors of nuclear factor κB activation and tumor necrosis factor (TNF)
production [13,14]. There is also direct genetic evidence that c-IAP1
and c-IAP2 can function as oncogenes. An amplification of the
11q21-23 chromosomal region, which encompasses the c-IAP1 and
c-IAP2 genes, is observed in a variety of malignancies including me-
dulloblastomas, renal cell carcinomas, glioblastomas, gastric carcino-
mas, and both small and non–small cell lung carcinomas [10].
Furthermore, both c-IAP1 and c-IAP2 are overproduced and con-
tribute to rapid tumor growth in human hepatocellular carcinomas,
whereas in esophageal carcinomas, it is only c-IAP1 that is overpro-
duced [15,16]. In this light, it seemed of interest to further investi-
gate the role of c-IAP2 in NPC cells.
Macrophages from c-IAP2 knockout mice show a high sensitivity
to apoptosis in a lipopolysaccharide (LPS)-induced proinflamatory
environment, which stimulates the Toll-like receptor 4 (TLR4) [17].
c-IAP2 could thus play a key role in response to TLR stimulation. The
TLRs are type I transmembrane proteins thought to be critically in-
volved in the detection of pathogens and in triggering inflammation
and immune response to microbial infections [18]. The stimulation
of TLRs by their respective ligands initiates well-characterized sig-
naling cascades that enhance cellular resistance against pathogens. Oc-
casionally, it also induces cell death, one of the mechanisms that
limit virus diffusion in the host. Toll-like receptors are expressed not
only in immune cells, but also in some cancer cells, opening the way
for TLR-based cancer therapy [19,20]. Among TLRs, TLR3 is spe-
cifically involved in antiviral responses triggered by the binding of
double-stranded RNA of viral origin. This binding leads in turn to
mitogen-activated protein kinases, nuclear factor κB, and interferon
regulatory factor 3 activation and to interferon I induction through
the adaptor proteins TIR domain-containing adapter-inducing IFN-β
(TRIF) and receptor-interacting protein (RIP) [18,21]. Moreover,
a direct proapoptotic effect of TLR3 agonists has been reported in
several tumor cells [22,23].
This work aimed to answer the following questions: Is c-IAP2
consistently overexpressed in NPC cells? Are NPC cells permanently
dependent on c-IAP2 overexpression? What are the specific functions
of c-IAP2 in NPC cells? We report that c-IAP2 plays a major role in
the resistance of NPC cells to apoptosis induced by TLR3 stimula-
tion, whereas it is not involved, or marginally involved, in NPC cell
response to other proapoptotic factors like TNF-α or cisplatin. Be-
cause NPC cells are known to produce large amounts of viral EBER
RNA, which are potential agonists of TLR3, our data will have im-
portant implications for our understanding of virus-cell interactions
and design of novel therapeutic strategies.
Materials and Methods
Clinical Specimens of NPCs and Immunohistology
Nasopharyngeal carcinoma biopsy fragments were obtained, before
treatment, from 13 NPC patients referred to the Institut Gustave
Roussy (9 patients; Villejuif, France) or the Sfax University hospital
(4 patients; Sfax, Tunisia). The clinical and pathologic character-
istics of these tumors are summarized in Table W1. Tumor pieces
were fixed in PBS–formaldehyde 4% for 16 hours and were paraffin-
embedded. Tissue sections were microwaved at 98°C for 30 minutes
in citrate buffer (10 mM, pH 7.3) and were incubated with an anti-
human c-IAP2 mouse monoclonal antibody (clone F30-2285; BD
Biosciences, San Jose, CA). Binding of the primary antibody was de-
tected with the CSA II kit from Dako (based on a tyramide amplifica-
tion system; DakoCytomation, Glostrup, Denmark).
Xenografts and Cell Lines
C15 and C17 are EBV-positive NPC xenografts routinely propa-
gated by subcutaneous passages into nude mice. Some data presented
in this report were obtained from C19, another NPC xenograft that
is no longer propagated into nude mice, for which frozen tumor
pieces and DMSO-frozen cells were available [24]. So far, it has
not been possible to establish long-term in vitro cultures from the
C15 and C17 xenografts. They can only be handled in short-term
in vitro cultures after mouse sacrifice, tumor dissection, and collage-
nase dispersion [8,25]. In contrast, C666-1, another EBV-positive
NPC cell line, can be propagated either as xenografts or by long-term
in vitro cultures [25,26]. In the rest of this report, C15, C17, and
C666-1 are often referred as “NPC tumor lines.” Persistence of latent
EBV infection in the C15, C17, and C666-1 xenografts was checked
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at regular time intervals by EBER hybridization (Figure W1). Pri-
mary cultures of nasopharyngeal epithelial cells were established in
Hong Kong from nonmalignant biopsies from the nasopharyngeal
region as previously described [27]. Nontumorigenic immortalized
epithelial cell lines were obtained from such primary cultures by
SV-40 infection (NP69 cells) or stable transfection of the gene encod-
ing the telomerase catalytic subunit hTert (NP460 cells) [27,28].
CNE2 is an atypical EBV-negative NPC cell line [24]. Non-NPC ma-
lignant cell lines were also used: HeLa (epithelial, cervix carcinoma),
A431 (epithelial, vulvar epidermoid carcinoma), and Jurkat derived
from a T-cell leukemia. MRC5 cells are human untransformed fibro-
blasts purchased from Biomerieux (Marcy l’Etoile, France) [29]. Before
in vitro experiments, C17 xenografted tumors were minced and treated
with type II collagenase for cell dispersion as previously reported
[8,24,25]. C666-1 cells were continuously grown in vitro in RPMI
1640 medium (Gibco-Invitrogen, Carlsbad, CA) supplemented with
25 mM HEPES and 7.5% fetal calf serum (FCS), in plastic flasks
coated with collagen I (Biocoat; Becton-Dickinson, Franklin Lakes,
NJ). NP69 and NP460 were grown in keratinocyte serum-free me-
dium (Gibco) supplemented with 10% FCS and 50 μg/ml bovine
pituitary extract for NP460 (Gibco). In some experiments requiring
precise comparisons with C15 and C17 xenografts, CNE2, HeLa,
and A431 cells were grown as xenografts into nude mice (subcutaneous
injections of 2 to 5million cells and tumor collection 3 to 4 weeks later).
RNA Extraction and Transcriptome Analysis
Detailed protocols for RNA extraction and transcription profiling
on microarrays are available from the ArrayExpress Repository
(http://www.ebi.ac.uk/microarray-as/) under the accession number
E-TABM-382. Briefly, total RNA was extracted from xenografted tu-
mors and cultured cells with the TriReagent method (Euromedex,
Souffelweyersheim, France) and further purified on RNeasy columns
(Qiagen, Valencia, CA). For transcription profiling on microarrays,
target cDNA were synthesized by incubating total RNA (25 μg) with
a cocktail containing Cy3 or Cy5-dUTP and SuperScript II reverse
transcriptase (Life Technologies, Gibco-Invitrogen). The microarray
slides used were pan-genomic oligo-arrays containing 22,000 60-mer
oligomers representative of 14,217 genes and were manufactured by
Agilent (Santa Clare, CA; ref. G 4110A). Labeled targets were hybrid-
ized with these slides for 16 hours at 42°C. The slides were washed and
scanned with an Agilent 2565AA DNA array scanner with a resolution
of 10 μm. Data were analyzed with the Rosetta Resolver system for
gene expression analysis (Rosetta Inpharmatics LLC, Seattle, WA).
Reverse Transcription–Polymerase Chain Reaction Analysis
Total RNA (1 μg) was reverse-transcribed using the Protoscript
First Strand cDNA Synthesis Kit (New England BioLabs, Ipswich,
MA). Real-time polymerase chain reaction (PCR) was performed
in a 25-μl reaction volume, containing 25 ng of cDNA template,
10 pmol of each primer, and 12.5 μl of SYBR-Green Master Mix
(Applied Biosystems, Foster City, CA) or TaqMan Universal PCR
Master Mix (Roche Molecular, Neuilly sur Seine, France). Baculoviral
IAP repeat-containing 3 (BIRC3) mRNA was amplified with the
following oligonucleotides: BIRC3-sense: 5′-ATCTGGAGATGAT-
CCATGGG-3′ and BIRC3-antisense: 5′-TGTTCAAGTAGATGA-
GGG-3′. Amplified GAPDH RNA was used as an endogenous
control. Amplification reactions were performed in an Applied Bio-
systems ABI Prism 7000 Sequence Detection System. Conventional
reverse transcription–PCR (RT-PCR) was used for the detection of
TLR3, 4, and 9 transcripts, using specific primer pairs from R&D Sys-
tems (Minneapolis, MN; RDP 266, 268, and 274, respectively).
Fluorescent In Situ Hybridization Analysis
Interphase nuclei and metaphase spreads were prepared according
to standard procedures from the C666-1 NPC cell line and, after
collagenase dispersion, from the C15, C17, and C19 NPC xeno-
grafts. The BIRC3 DNA probe was derived from the BAC clone
RP11-659L4, starting at nucleotide 101,609,259 and ending at
nucleotide 101,837,762 (BacPac Resources, Children’s Hospital,
Oakland, CA). This BAC clone contains the entire BIRC3 gene,
running from nucleotide 101,693,404 to 101,713,658 on 11q22.2
(http://www.genome.ucsc.edu/). This probe was labeled by random
priming with fluorescein 5-dUTP (Abbot-Vysis, Downers Grove,
IL). It was then tested for fluorescent in situ hybridization on normal
metaphases to ensure that it hybridized specifically with the target
chromosome. The same BAC was then hybridized with interphase
nuclei and metaphases from the four NPC tumor lines, according
to a previously published protocol [30].
Treatments of Cells with Pharmacological Reagents
and siRNA
The polycyclic C2-symmetric (40 carbon atoms) compound RMT
5265, which mimics the three-dimensional structure of the second
mitochondria–derived activator of caspases (Smac)/Diablo N-terminal
tetrapeptide, has been described elsewhere [31]. HS4044 has a simi-
lar structure but is acetylated at a critical alanine group; it was used
as a negative control [31]. Both reagents were dissolved in DMSO.
Caspase-8 was inhibited with Z-IETD-FMK (N-1830; Bachem,
Bubendorf, Switzerland) at a concentration of 50 μM. The proteasome
was neutralized by incubation with 10 μM MG132 (Calbiochem,
San Diego, CA) or 1 μM epoxomicin (Calbiochem) for 15 min-
utes. As a positive control for apoptosis induction, cells were treated
with a Fas agonist, the monoclonal antibody 7C11, at a concen-
tration of 100 ng/ml for 6 hours (Immunotech, Beckman-Coulter,
Fullerton, CA). Agonists of TLR3 (poly(I:C)) and TLR9 (type C
CpG) were obtained from InvivoGen (San Diego, CA). TNF-α
(Peprotech, Rocky Hill, NJ) toxicity was verified on MCF7 cells.
cis-Platinum(II)diammine dichloride (cisplatin) was purchased from
Sigma (St. Quentin Fallavier, France). C666-1 cells at 30% to 50%
confluence in six-well plates were transiently transfected with siRNA.
For RNA interference, double-stranded RNA oligonucleotides directed
against c-IAP2 (a: HSS100562, b: HSS100561), XIAP (a: HSS100566,
b: HSS100565), survivin (a: HSS141243, b: HSS141245), and a nega-
tive control (1390109) were purchased from Invitrogen. Transfections
were carried out using Oligofectamine (Invitrogen). Two successive
rounds of siRNA transfection at 48-hour intervals were required for
the efficient depletion of c-IAP2.
Cell Growth and Viability Assays
The clonal growth of C666-1 NPC cells was assessed using a feeder
layer of Swiss 3T3 murine fibroblasts as previously described [32].
Briefly, irradiated Swiss 3T3 cells kindly provided by T. Magnaldo
(Institut Gustave-Roussy, Villejuif, France) were plated in six-well
plates (1.5 × 105 per well). Once the fibroblasts had adhered to
the plate, epithelial cells were added at a density of 500 (immortal-
ized NP69 cells) to 5000 cells per well (C666-1 NPC cells). After 2
to 4 weeks of culture, cell colonies were stained with a solution of
crystal violet in methanol. Alternatively, the viability of C666-1 cells
Neoplasia Vol. 10, No. 11, 2008 c-IAP2/TLR3 Regulation of Apoptosis in Carcinomas Friboulet et al. 1185
was determined in a short-term assay based on the reduction of WST
(a soluble form of MTT; Roche Molecular), as previously described
[25]. For this assay, cells were seeded in 96-well plates at a density
of 3 × 104 cells per well. The WST reaction was performed after
72 hours of culture. The growth of C17 NPC cells in vitro was
evaluated with a short-term colony assay. Dispersed cells derived
from xenografted tumors were seeded in 24-well plates at a density
of 106 cells per well in 1.5 ml in RPMI 1640 medium (Gibco-
Invitrogen) supplemented with 25 mM HEPES and 20% FCS.
The culture medium was changed twice, 16 and 72 hours later. At
the second medium change, the concentration of FCS was decreased
to 7.5%. During the next 3 days, scattered colonies of epithelial cells
became apparent on a layer of murine fibroblasts. These colonies
were stained with rhodamine in 4% formaldehyde in PBS and
counted under an inverted microscope.
Assessment of Apoptosis and Caspase Activation
Apoptosis was assessed quantitatively by determining the sub-G1
DNA content in ethanol-fixed cells, stained with propidium iodide
and analyzed using a Becton Dickinson FACScalibur flow cytometer
and the CellQuest Pro software. Alternatively, apoptosis was evalu-
ated by the detection of the cleavage of poly(ADP-ribose)polymerase
(PARP) by Western blot analysis performed on total cell protein
extracts (see next paragraph). The activities of caspases-3/7 and
caspase-8 were measured with the Caspases-Glo 3/7 and Caspases-
Glo 8 Assay kits, respectively (Promega, Madison, WI). These assays
are based on the cleavage of luminogenic substrates containing the
amino acid sequences Z-DEVD and Z-LETD, respectively.
Cell Protein Extraction and Western Blot Analysis
Proteins from cultured cells or xenografts were extracted by lysis in
RIPA buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.5% so-
dium deoxycholic acid, 0.5% NP-40, 0.1% SDS) supplemented with
a protease inhibitor cocktail (Complete; Roche Molecular). They were
separated by SDS-PAGE and transferred to polyvinylidene difluoride
membranes (Immobilon, Millipore, Billerica, CA) by electroblot analy-
sis at 4°C for 90 minutes at 90 V or overnight at 45 V. The antibodies
used for Western blot analysis were mouse monoclonal antibodies di-
rected against human c-IAP2, XIAP, and c-IAP1, obtained from BD
Biosciences (refs. 552782, 610763, and 556533, respectively). The
other mouse monoclonal antibodies used were specific for Smac/
Diablo (ref. 9494; Cell Signaling, Danvers, MA), survivin (ref. 17779;
Santa Cruz Biotechnology, Santa Cruz, CA), PARP (clone C-2-10,
ref. 53643; Santa Cruz Biotechnology), and FLICE-like inhibitory
protein (FLIP, ref. 804-428; Alexis Biochemical, San Diego, CA). Blots
were incubated with a secondary peroxidase-conjugated antibody, and
chemiluminescent detection was done using the Immobilon Western
Chemiluminescent HRP Substrate (Millipore). When required, the
probe was removed from the blot by incubating in Re-Blot Plus Mild
Antibody Stripping Solution (Chemicon, Millipore) for 20 minutes at
room temperature. In one instance, c-IAP2 was immunoprecipitated
before Western blot analysis using magnetic beads, according to our
previously described protocol [33].
Statistics
Results of functional tests—colony, viability, and caspase assays—
were given as the means ± SD. Statistical significance was assessed using
a 2-tailed Student’s t test for comparison of two experimental condi-
tions. When making comparisons involving multiple experimental con-
ditions, we used the analysis of variance test completed by the Tukey
test (bilateral) in the XLSTAT software (95% confidence interval).
Results
Abundant Transcription of the BIRC3 Gene in NPC Cells,
Even in the Presence of Hemizygous Deletions
To analyze the cellular part of NPC oncogenesis, we assessed gene
expression profiling on two NPC xenografts (C15 and C17) on
Agilent microarrays containing 22,000 oligonucleotides represen-
tative of 14,217 genes using untransformed quiescent human fi-
broblasts (MRC5) as a reference. All data are available from the
ArrayExpress Repository (http://www.ebi.ac.uk/microarray-as/; under
the accession number: E-TABM-382). We focused subsequent inves-
tigations on genes transcribed at very high levels in each xenograft.
The main characteristics of the top 13 most transcribed genes, includ-
ing their chromosomal location, are provided in Table W2. BIRC3,
encoding the c-IAP2 protein, was one of these genes. Its consistent
overexpression was confirmed by quantitative RT-PCR (Figure 1A).
BIRC3 transcripts were much more abundant in EBV-positive NPC
tumor lines (either xenografted or propagated in vitro)—C15, C17,
C19, and C666-1—than in any other cell type, including untrans-
formed MRC5 fibroblasts, non-NPC malignant epithelial cells (HeLa,
A431), atypical EBV-negative NPC cells (CNE2), and a primary cul-
ture of nasopharyngeal epithelial cells (NP) from normal mucosa.
Meanwhile, we noticed the BIRC3 gene maps to a chromosomal band
(11q22) frequently affected by hemizygous deletions in NPCs and in
certain other tumor types [26,34,35]. From our previous studies, it is
known that the 11q22 band is affected by hemizygous losses in C17,
C19, and C666-1 but not in C15 [26,34]. Accordingly, BIRC3 was ex-
pected to be reduced to one copy in C17, C19, and C666-1 but not in
C15 cells. This was verified by fluorescent in situ hybridization analysis
using a BAC probe encompassing the BIRC3 gene (Figure 1B). Thus,
the reduction of the BIRC3 gene to a single copy was not accompanied
by a significant decrease in its level of transcription, which remained in
the same order of magnitude as for the C15 xenograft. This was par-
ticularly striking because most genes mapping to chromosome 11q22
displayed a marked decrease in expression (complete data provided in
the ArrayExpress repository, accession number: E-TABM-382). These
observations suggested that BIRC3 overexpression could provide a se-
lective advantage on NPC cells even at a late stage of tumor progres-
sion (e.g., in C17 and C19 xenografts that had been derived from
metastatic cells).
Recurrent Overproduction of the c-IAP2 Protein in NPC
Tumor Lines and Clinical Specimens
We next investigated whether the overexpression of BIRC3 at the
mRNA level was accompanied by a high level of c-IAP2 protein
in NPC cells. Western blot analysis was performed on three NPC
tumor lines and several reference cells, including non-NPC malig-
nant epithelial cells (xenografted HeLa cells), atypical EBV-negative
NPC cells (xenografted CNE2 cells), nonmalignant human fibro-
blasts grown in vitro (MRC5), and nonmalignant nasopharyngeal
epithelial cells immortalized by SV40 infection (NP69) or telomerase
gene transfection (NP460) [27,28]. As shown in Figure 1C , the
c-IAP2 protein levels were consistent with those obtained at mRNA
level. A very high concentration of c-IAP2 protein was found specifi-
cally in NPC tumor lines, in which this protein was approximately
10-fold more abundant than in non-NPC xenografts, MRC5 cells,
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or immortalized nasopharyngeal cells. In the subsequent stages of
our study, we never found a cell type with a c-IAP2 content higher
than those of NPC cells. In contrast, in Figure 1C , the expression
level of XIAP was equally abundant in all cell types, including non-
malignant MRC5 cells. Survivin was present in similar large amounts
in NPC and non-NPC tumor lines but in only small amounts in
MRC5 cells. c-IAP1 was abundant in the Jurkat T-cell line used as
a positive control, whereas it was barely detectable in other cell types,
including the NPC tumor lines. Importantly, those results were con-
firmed in tissue sections from clinical NPC specimens. High levels of
c-IAP2 expression were found in 11 of 13 biopsies (Figure 1D and
Table W1). Its distribution was essentially cytoplasmic with only rare
examples of nuclear localization. c-IAP2 expression was consistently
more intense in malignant NPC cells than in the lymphoid stroma
Figure 1. Recurrent overproduction of the c-IAP2 protein in NPC tumor lines and clinical specimens despite hemizygous losses of
BIRC3. (A) Assessment of BIRC3 gene expression by real-time RT-PCR. Amounts of BIRC3 transcripts were deduced from C t values
and normalized with values obtained from GAPDH RNA amplifications. Relative levels of expression are given, with the value obtained
for C666-1 NPC cells arbitrarily set at 1. For accurate comparisons with NPC xenografts, CNE2, HeLa, and A431 cells were grown as
xenografts before RNA extraction. Human untransformed MRC5 fibroblasts, which are sensitive to contact inhibition, were collected as
quiescent cells after 3 days of growth arrest resulting from cell confluence. (B) Fluorescent in situ hybridization detection of the BIRC3
gene on interphase nuclei and metaphases of NPC cells. The images were acquired with a color CCD camera using the Smart Capture
program (Digital Scientific, UK). Three of four NPC tumor lines (C666-1, C17, and C19) displayed alterations to chromosome 11q result-
ing in the deletion of one copy of the BIRC3 gene as shown by the detection of a single spot on interphase nuclei. By contrast, the cells
from the C15 xenograft retained two copies of the BIRC3 gene. Hybridizations on chromosome spreads were obtained for three tumor
lines. Consistent with observations on interphase nuclei, C666-1 and C17 cells displayed BIRC3 spots linked only to one chromosome
11 (with a double spot due to the presence of two chromatides after completion of the “S” phase). By contrast, C15 cells contained
BIRC3 spots linked to two chromosomes 11 (each chromosome containing a double spot). (C) Left panel, Western blot analysis of
c-IAP2, XIAP, c-IAP1, survivin, and Smac in NPC and non-NPC cell lines. Right panel, Western blot analysis of IAP proteins in immor-
talized nontumorigenic nasopharyngeal epithelial cells: NP69 (SV40 infection) and NP460 (telomerase transfection). (D) Detection of
c-IAP2 by immunohistochemistry on tissue sections of NPC specimens using the F30-2285 monoclonal antibody. Panel 1 (original mag-
nification, ×400): C666-1 cells grown as a xenografted tumor showing intense cytoplasmic expression consistent with the Western blot
analysis data displayed in panel (C). Panel 2 (original magnification, ×400): HeLa cells grown as a xenografted tumor; no c-IAP2 staining
is visible, although a faint band was detected by Western blot analysis (panel C), which is more sensitive than immunohistochemistry.
Panels 3 (original magnification, ×200) and 4 (original magnification, ×400): cytoplasmic staining of c-IAP2 in biopsies 4 and 7, respec-
tively; note the intense expression in malignant cells, contrasting with the very weak expression in stromal cells.
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or in adjacent residual non malignant mucosa. The abundance of
c-IAP2 in patient biopsies was in favor of its important role in
NPC tumor growth in situ.
RMT 5265 Induces the Proteasome-Mediated
Degradation of c-IAP2
Data from previous experiments supported the hypothesis of a
critical role of c-IAP2 in NPC cell growth. To test this hypothesis by
functional inhibition in vitro, we first resort to RMT 5265, a pharma-
cological inhibitor of IAP proteins. This compound is a molecular
mimic of the N-terminal AVPI sequence of the mature Smac-Diablo
protein. It is known to bind c-IAP1, c-IAP2, and XIAP [14,31]. To
get formal evidence of its inhibitory effect on c-IAP2, we monitored
c-IAP2, XIAP, and survivin content of cells treated with RMT 5265.
A marked, dose-dependent decrease in c-IAP2 levels—but not in
those of XIAP and survivin—was observed in all cell types tested, in-
cluding C666-1 NPC cells, HeLa cells, and NP69 nonmalignant na-
sopharyngeal cells (Figure 2A). c-IAP2 levels decreased dramatically
and very rapidly, reaching a minimum in less than 1 hour (Fig-
ure 2B). This decrease was prevented by prior treatment with two pro-
teasome inhibitors, MG132 and epoxomicin (Figure 2C ). A ladder
highly suggestive of the presence of ubiquitinated forms of c-IAP2
was visualized by immunoprecipitation and Western blot analysis of
c-IAP2 from C666-1 cell extracts. The amount of proteins present
in this ladder increased substantially if C666-1 cells were treated with
RMT 5265 for 15 minutes, suggesting that the proteasome-mediated
degradation induced by RMT 5265 resulted from the enhanced poly-
ubiquitination of c-IAP2 (Figure 2D). The above experiments demon-
strated that in NPC cells c-IAP2 was a major target of RMT 5265 and
justified the subsequent use of this compound for pharmacological
inhibition of c-IAP2 functions in these cells.
RMT 5265 Selectively Blocks the Clonogenic
Growth of NPC Cells
On the basis of our previous results, we used RMT 5265 to assess
the influence of c-IAP2 inhibition on NPC cell growth. Although
c-IAP2 was degraded by RMT 5265 in all cell types, the inhibition
of clonogenic growth was observed only in NPC cells. A concentra-
tion of 50 nM RMT 5265 was sufficient to abolish the growth of
C666-1 cells with little or no effect on nonmalignant nasopharyn-
geal cells (NP69 and NP460; Figure 3A). To confirm the inhibition
of NPC cell growth by RMT 5265, using cells distinct from the
Figure 2. Proteasome-dependent degradation of c-IAP2 induced by
RMT 5265. (A) Upper panel, selective and dose-dependent de-
crease in c-IAP2 concentration in C666-1 cells treated with RMT
5265 or control compound (HS4044). Cells were collected after
48 hours of treatment. Specific protein bands were quantified
by film densitometry using a GS-710 calibrated imaging densito-
meter with Quantity One software (Biorad, Marnes la Coquette,
France). The decrease in c-IAP2 concentration is marked and
dose-dependent. Survivin is not affected. The concentration of XIAP
was apparently modified for low but not for high concentrations
of RMT 5265. These variations were not regarded as significant.
Lower panel, a similar decrease in c-IAP2 concentration was in-
duced by RMT 5265 in HeLa and NP69 cells. (B) Kinetics of the de-
crease in c-IAP2 concentration induced by RMT 5265 in C666-1
cells. (C) The decrease in c-IAP2 concentration induced by RMT
5265 was prevented by prior incubation (15 minutes) and concomi-
tant incubation with the proteasome inhibitors MG132 or epoxomi-
cin. (D) RMT 5265 increased the amount of ubiquitinated forms of
c-IAP2 detected in C666-1 cells. Immunoprecipitation was carried
out before Western blot analysis to increase the signal-to-noise
ratio for the detection of all forms of c-IAP2. Treatment by RMT
5265 enhanced the detection of a ladder of minor c-IAP2 species
with a spacing of approximately 8 kDa, highly suggestive of a poly-
ubiquitination process. Control agent and RMT 5265were used at a
100-nM concentration.
1188 c-IAP2/TLR3 Regulation of Apoptosis in Carcinomas Friboulet et al. Neoplasia Vol. 10, No. 11, 2008
C666-1 model, we resort to the C17 NPC xenograft. Although C17
cells cannot be permanently propagated in vitro, we were able for the
first time to perform a short-term colony assay using this material.
We could show that the viability and/or proliferation of C17 NPC
cells were significantly decreased by RMT 5265 (Figure 3B). Al-
together, these results suggested that NPC cells were dependent on
a high expression of c-IAP2, whereas c-IAP2 expression in nonmalig-
nant nasopharyngeal cells was both consistently low and dispensable
for clonogenic growth.
RMT 5265 Induces Apoptosis in a Fraction of NPC Cells
Because IAP functions are mainly related to apoptosis control we
then investigated whether the toxicity of RMT 5265 to NPC cells
involved apoptosis. C666-1 cells were treated in short-term experi-
ments (48 hours) with two concentrations of RMT 5265 (50 or
200 nM), and the rate of apoptosis was assessed by flow cytometry
measurements of the sub-G1 fraction. As shown in Figure 4, approxi-
mately 30% of C666-1 cells became apoptotic with a concentration
of RMT 5265 as low as 50 nM. In contrast, there was no apoptosis
induction in HeLa cells and nonmalignant nasopharyngeal epithelial
cells (NP69) with concentration of RMT 5265 as high as 200 nM.
This absence of apoptotic response was observed despite the fact that
c-IAP2 was almost completely degraded under treatment by RMT
5265 (Figure 2A). This was one additional observation supporting
the hypothesis that permanent high expression of c-IAP2 was obliga-
tory in NPC cells, whereas its low-level expression was dispensable in
nonmalignant nasopharyngeal epithelial cells (NP69) or non-NPC
carcinoma cells (HeLa cells).
RMT 5265 Unmasks a High Sensitivity of NPC Cells to
TLR3-Mediated Apoptosis
To obtain more information about the antiapoptotic functions of
c-IAP2 in the context of NPC cells, treatment by RMT 5265 was
combined with various potential apoptotic stimuli, especially some
likely to occur in a context of local inflammation. A previous study
showed that c-IAP2 knock-out in mice results in the complete inver-
sion of the monocyte response to LPS, a specific agonist of the TLR4
receptor. In mice with a KO for c-IAP2, LPS induces monocyte
apoptosis instead of monocyte activation [17]. In humans like in
other mammals, TLRs are key effectors of tissue inflammation,
and several of them, including TLR3, 4, and 9, are frequently ex-
pressed by carcinoma cells [20,22]. Therefore, we considered the hy-
pothesis that c-IAP2 could modulate the response of NPC cells to
TLR stimulation. To address this hypothesis, TLR expression was
characterized in three NPC tumor lines (C15, C17, and C666-1).
TLR3 and TLR9 transcripts were detected by RT-PCR in all three
specimens, whereas TLR4 was detected only in C15 (Figure 5A).
Consequently, we focused our study on TLR3 and 9 and checked
the impact of their activation on NPC cells. In short-term growth
assays, C666-1 viability and proliferation were decreased at best mar-
ginally by TLR9 agonists, TNF-α and cisplatin, either alone or in
combination with RMT 5265 (Figure 5B). By contrast, treatment
with the TLR3 agonist (poly(I:C)) combined with RMT 5265 had a
highly cytotoxic effect on C666-1 cells, even at concentrations of 100
to 500 ng/ml, which are very small by comparison with concentrations
routinely used in most other studies dealing with TLR3 (usually in the
range of 5-10 μg/ml; Figure 5B) [23]. The same growth-inhibitory
effect was obtained in a short-term colony assay performed on cells
from the C17 xenograft (Figure 5C ). The number of colony was
Figure 3. Selective inhibitory effects of RMT 5265 on NPC cell
growth in vitro. (A) Clonogenic growth of NPC cells (C666-1) and
immortalized nasopharyngeal epithelial cells (NP69 and NP460)
treated with RMT 5265. Cells were seeded at low density in six-
well plates, on a feeder layer of irradiated Swiss 3T3 fibroblasts,
as described in the Materials and Methods section. Initial cell den-
sity: C666-1 cells: 5000 cells per well; NP69: 500 cells per well;
NP460: 2500 cells per well. Culture medium and treatment were
renewed twice a week. Colonies were stained with crystal violet
after two to four weeks of growth. (B) Short-term colony assay per-
formed on C17 NPC cells treated with RMT 5265, control agent
(HS4044), or left untreated. Cells obtained by dispersion of C17
xenografts were seeded on day 1 at high density (1.2 × 106 cells
per well in 24-well plates) and treated with pharmacological agents
from days 4 to 7. During this period, dead cells were progressively
removed through partialmediumchanges. At the completion of this
period, cell colonies were stained with rhodamine and numbered
under an inverted microscope. Colony numbers were the mean of
three counts made for three separate wells on 24-well plates. For
star-marked conditions, the differences in colony numbers with
the control condition were statistically significant (P < .05).
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reduced by 11-fold in the presence of RMT 5265 combined with
poly(I:C). The cytotoxic effect of the combined treatment on NPC
cells was accounted for by apoptosis, at least to a large extent, as in-
dicated by its impact on caspase-3/7 activation in C666-1 cells (data
obtained by caspase chemiluminescence assays are presented in Fig-
ure 5D). Caspase-3/7 activity was increased fourfold in the presence
of RMT 5265, whereas it was increased ninefold with the combined
treatment. By contrast, no induction of caspase-3/7 was obtained in
nonmalignant nasopharyngeal cell lines (NP69 and NP460) treated
by RMT 5265 or the combined treatment (data not shown).
Apoptosis Induced by RMT 5265 Combined with TLR3
Stimulation Is Dependent on Caspase-8 Activation
Previous studies on other tumor models have shown that RMT
5265 induces apoptosis by RIPK1-dependent caspase-8 activation in
several host cells [13,14]. Conversely, TLR3 is known to activate
caspase-8 through a TRIF-RIPK1-FADD pathway in 293 cells [21].
We therefore investigated the contribution of caspase-8 to the apopto-
tic process induced in the three NPC tumor lines—C666-1, C15, and
C17—by RMT 5265 combined with TLR3 stimulation (Figure 6A).
Figure 4. Short-term effects of RMT 5265 treatment in C666-1
NPC cells. Flow cytometry assessment of DNA content and count-
ing of cells with sub-G1 characteristics. Treatment with 50 nM RMT
5265 for 48 hours increased the fraction of sub-G1 cells to 30%
with no substantial change at a higher concentration of RMT
5265 (200 nM). In contrast, the fraction of sub-G1 cells was not
increased by RMT 52656 in non-NPC carcinoma cells (HeLa) or in
nonmalignant nasopharyngeal epithelial cells (NP69).
Figure 5. RMT 5265 unmasks the sensitivity of NPC cells to TLR3-
mediated apoptosis. (A) Transcription of TLR genes assessed by
RT-PCR in three NPC tumor lines. Toll-like receptor 3 (601 bp)
and TLR9 (451 bp) amplicons are detected in all three tumor lines.
Two TLR4-specific amplicons (409 and 242 bp) are detected in
C15 but not in C666-1 and C17. (B) Short-term growth assay for
C666-1 cells treated for 72 hours with various concentrations of
TLR3 (poly(I:C)) or TLR9 (CpG) agonists (upper panel) or TNF-α
or cisplatin (lower panel) combined with RMT 5265 (100 nM) or
control agent (100 nM). Numbers of viable cells were evaluated
based on the reduction of WST, a soluble form of MTT, as ex-
plained in the Materials and Methods section. Each measurement
was done in triplicate. (C) Counting of C17 NPC cell colonies af-
ter 3 days of treatment with poly(I:C) combined with RMT 5265
(100 nM) or control agent (100 nM). The procedure used for this
short-term colony assay was as described in the legend of Figure 3B.
Colony numbers were the mean of three counts made for three
separate wells on 24-well plates. (D) Chemiluminescence assay of
caspases-3/7 activity in C666-1 cells after 48 hours of treatment with
various concentrations of poly(I:C) combined with RMT 5265 or
control agent (100 nM). Each measurement was done in duplicate.
All data in this figure are representative of at least three similar ex-
periments. The stars indicate statistical differences from respec-
tive controls or other experimental conditions (P < .05).
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Figure 6. Role of caspase-8 activation in apoptosis induced by TLR3 stimulation combined with RMT 5265. (A) Assay of caspase-8 ac-
tivity (chemiluminescence) in three NPC tumor lines C666-1, C15, C17, treated for 16 hours with poly(I:C) (500 ng/ml) combined with
RMT 5265 or control agent (100 nM). Each measurement was done in duplicate. Cells not used in the caspase-8 assay were saved for
protein extraction in RIPA and Western blot detections of c-IAP2, FLIP-L, and PARP. (B) Caspase-8 assay, FLIP-L detection (Western
blot), and PARP cleavage assay (Western blot) for C666-1 cells treated with various combinations of the following reagents: RMT 5265,
poly(I:C), and a caspase-8 inhibitory peptide (Z-IETD-FMK) (50 μM). The caspase-8–inhibitory peptide was added 1 hour before poly(I:C)
and/or RMT 5265. Cells were collected for protein extraction 16 hours later. (C) Caspase-8 assay in NP69 cells treated for 16 hours with
poly(I:C) (500 ng/ml) combined with RMT 5265 or control agent. All data in this figure are representative of at least two similar experi-
ments. The stars indicate a statistical difference from respective controls (P < .05).
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Caspase-8 activation and PARP cleavage were monitored as well as
c-IAP2 and FLIP-L cellular concentrations (FLIP is an important
regulator of caspase-8 activity with predominant inhibitory effects
of the long isoform FLIP-L) [36]. In the absence of any treatment,
low levels of constitutive caspase-8 activity were detected in all
three NPC tumor lines. By itself, RMT 5265 treatment led to a
substantial decrease in c-IAP2 concentration accompanied by a
mild increase in caspase-8 activity and a small increase in PARP
cleavage in two of the three NPC tumor lines (C666-1 and C17).
By itself, treatment with poly(I:C) induced amild increase in caspase-8
activity without significant changes regarding other molecules. Fi-
nally, combination of both treatment induced a dramatic decrease
in c-IAP2 and FLIP-L concentrations combined with a strong in-
crease in caspase-8 activity and PARP cleavage in all three tumor lines,
although this cooperative effect was at its highest magnitude in
C666-1 cells. In the next experiment, using a membrane-permeable
inhibitor of caspase-8 (Z-IETD-FMK), we intended to determine
whether the cleavage of PARP and the decrease in FLIP-L concentra-
tion were dependent on caspase-8 activation (Figure 6B). Again, a
strong increase in caspase-8 activity and a marked decrease in FLIP-L
concentration was achieved by the combined treatment (RMT 5265 +
poly(I:C)). Remarkably, caspase-8 inhibition completely abrogated
PARP cleavage but did not restore the normal level of FLIP-L, indicat-
ing that the low level of FLIP-L is not a consequence of its degrada-
tion by caspase-8 and suggesting a change in its regulation occurring
upstream of caspase-8 activation. Conversely, experiments displayed
in Figure 6C showed that a treatment combining RMT 5265 with
poly(I:C) had no significant effects on caspase-8 activation in non-
malignant nasopharyngeal epithelial cells (NP69).
Cooperation Between siRNA Inhibition of c-IAP2 and TLR3
Stimulation in Caspase-8 Activation in NPC Cells
In our previous experiments, despite the absence or the low level
of XIAP protein degradation induced by RMT 5265, functional in-
terference with XIAP could not be excluded. Therefore, to confirm a
specific role of c-IAP2 in blocking caspase-8 activation induced by
TLR3 stimulation in NPC cells, we resorted to a series of siRNA
specific of various IAPs. These siRNA were selected to minimize
cross-inhibition (Figure 7A). As shown in Figure 7B, a mild increase
in caspase-8 activity was observed when nonspecific siRNA as well
as XIAP and survivin siRNA were combined with TLR3 stimulation.
However, the greater cooperative effect was obtained with the c-IAP2
siRNA, and the differences with the other combinations were statis-
tically significant. In addition, a stronger PARP cleavage was detected
when the c-IAP2 siRNA was associated to TLR3 stimulation (notice
the decrease in the amount of the uncleaved form in addition to the
increase in the cleaved form). A concomitant decrease in FLIP-L con-
centration was also recorded. Overall, these data are similar to the
data obtained with the combination of RMT 5265 and poly(I:C)
and confirm the specific role of c-IAP2 in preventing caspase-8 acti-
vation by TLR3 agonists in NPC cells.
Discussion
There is ample evidence to suggest that antiapoptotic proteins are
essential for cancer cell proliferation and development [37]. This is
largely due to the frequent association of cell transformation by viral
or cellular oncogenes with the permanent activation of proapoptotic
pathways, which must be balanced by antiapoptotic mechanisms
supported by proteins such as those of the IAP family [11,38].
One IAP protein—survivin—is consistently overexpressed in most
of human malignancies. Nasopharyngeal carcinoma does not make
an exception to this rule as shown by previous publications and
our own results in this study [12,39] (Figure 1). By contrast, the dis-
tribution of c-IAP1 and c-IAP2 is highly variable depending on the
tumor types. Here, we have revealed a specific pattern of IAP expres-
sion in NPC cells. c-IAP2 is consistently produced in very large
amounts, whereas c-IAP1 is barely detectable. This pattern is the re-
verse of that reported in certain other tumors, such as esophageal car-
cinomas, in which c-IAP1 is overproduced in a context of low c-IAP2
expression [16]. It means that specific functions of c-IAP 1 and 2
should be considered depending on the tumor type. Elucidation of
these functions is expected to be important to understand which
pathways could provide the best targets for pharmacological action.
After showing that c-IAP2 is consistently overexpressed in NPC
specimens, we intended to demonstrate that NPC cell growth is de-
pendent on its presence at a high concentration. This aim was
achieved in a large extent by the use of the RMT 5265 inhibitor,
which blocked clonogenic growth of the C666-1 and C17 tumor
lines but not the growth of the nonmalignant nasopharyngeal epi-
thelial cells NP69 and NP460. Although we cannot exclude a con-
tribution of XIAP inhibition to the interruption of NPC cell growth
mediated by RMT 5265, two lines of evidence strongly suggest that
c-IAP2 is the major target of this drug in NPC cells: 1) regardless of
the cellular background, RMT 5265 induced a very rapid and strong
decrease in c-IAP2 levels (Figure 2); 2) although NP69 and NP460
cells contain XIAP levels comparable to NPC cells, they are not sen-
sitive to RMT 5265 (Figures 1 and 3).
Regarding our third question about a specific antiapoptotic func-
tion of c-IAP2 in NPC cells, we have shown its role in preventing
TLR3-mediated apoptosis. This conclusion is supported both by
pharmacological and siRNA inhibition of c-IAP2. For caspase-8 acti-
vation, siRNA specific of c-IAP2 are much more efficient than those
directed to XIAP or survivin when combined with TLR3 stimula-
tion. This finding opens interesting perspectives for a better under-
standing of virus-cell interactions in NPC. As pointed out above,
NPC cells produce large amounts of small EBV-encoded RNA with
partially double-stranded structures named EBERs [1]. Most EBERs
are contained in the nucleus but some are transported to the cyto-
plasm and, probably, to the extracellular medium. EBERs have been
shown to have signaling activity outside the nucleus of EBV-infected
cells [6]. For example, they induce insulin-like growth factor 1, pos-
sibly by stimulating TLR3 receptors [40]. This secreted insulin-like
growth factor 1 has autocrine growth-promoting activities [40]. Our
data show that TLR3 stimulation in NPC cells also has apoptosis-
inducing effects that are antagonized by c-IAP2. This may account
for the susceptibility of NPC cells to the long-term effects of RMT-
5265 when it is used alone. This compound may render NPC cells
sensitive to the cytotoxic effects of a permanent, low-level stimulation
of TLR3 receptors by endogenous EBERs, a point that will deserve
further investigation.
The mechanism of caspase-8 activation by c-IAP2 inhibition and
much more strikingly by the combination of c-IAP2 inhibition and
TLR3 stimulation is not yet elucidated. Two recent publications
based on other tumor models have recently reported that caspase-8 ac-
tivation by c-IAP2 inhibition is mediated by an increase in the se-
cretion of endogenous TNF-α and the autocrine stimulation of
the TNF-R1 receptor [13,14]. Experiments made in our NPC tumor
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lines suggest that the same mechanism is at least in part applicable
to our model (data not shown). Nevertheless, we noticed a decrease
in FLIP-L cellular content triggered by the combined treatments
(Figures 6 and 7). This change occurring upstream of caspase-8 ac-
tivation might also have a causative role in apoptosis induction by
the combined treatment. A marked decrease in FLIP-L content
was also observed using survivin siRNA; there are other examples
in the literature of parallel changes in FLIP-L and survivin cellular
contents [41].
The mechanism of c-IAP2 overexpression in NPC cells has not
been addressed in this study. c-IAP2 gene transcription is known
to be transactivated in certain cell types by the EBV oncoprotein
LMP1 [42]. However, c-IAP2 is strongly expressed in the C17 and
C666-1 tumor lines that lack LMP1 expression ([43] and data not
shown). We are currently investigating possible transactivation mecha-
nisms by other EBV latent products contained in NPC cells.
Finally, various types of pharmacological c-IAP2 inhibitors and
TLR3 agonists are currently in clinical trials [11,19]. Combinations
of both types of agents might be beneficial for NPC patients. The
benefits of this strategy may even extend to patients experiencing
other malignancies.
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Figure 7. Caspase-8 activation induced by TLR3 stimulation combined with IAP RNA interference. (A) Impact of siRNA on the cel-
lular concentration of c-IAP2, XIAP, and survivin assessed by Western blot detection (specific protein bands were quantified by film
densitometry using a GS-710 calibrated imaging densitometer with the Quantity One software; Biorad). (–) indicates no siRNA; NS:
non-specific siRNA. (B) Caspase-8 assay (chemiluminescence), c-IAP2, XIAP, and FLIP-L detection (Western blot) and PARP cleavage
assay (Western blot) in C666-1 undergoing knockdown of various IAPs with or without poly(I:C) treatment. Cells underwent two rounds
of siRNA transfection at 48-hour intervals. NS indicates nonspecific siRNA. Treatment with poly(I:C) was started 32 hours after the
second transfection, and cells were collected 16 hours later for protein extraction and caspase-8 assay. Each measurement was done
in duplicate. The star indicates a statistical difference from nonspecific siRNA combined with poly(I:C) (P < .05).
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Table W1. Detection of the c-IAP2 Protein by Immunohistochemistry on Tissue Sections from NPC Biopsies.
Patient No. Origin Sex/Age (years) Clinical Stage Histologic Subtype (WHO Classification) c-IAP2 Staining
1 Portugal M/50 T4 N2 M0 Type III +
2 Tunisia M/58 T1 N2 M0 Type III ++
3 Morocco M/59 T3 N1 M0 Type III +
4 Tunisia M/71 T2 N0 M0 Type II ++
5 France M/55 T3 N3 M0 Type II +
6 Malaysia M/47 T2 N0 M0 Type III +
7 Algeria M/58 T3 N2 M0 Type III +
8 Algeria F/33 T2 N2 M0 Type II +
9 Algeria M/72 T2 N2 M0 Type III +/−
10 Tunisia M/47 T3 N2 M+ Type II ++
11 Tunisia F/55 T4 N3 M+ Type II −
12 Tunisia M/38 T2 N2 M0 Type III ++
13 Tunisia M/40 T2 N3 M0 Type III ++
Images for cases 4 and 7 are displayed in Figure 1D.
M0 indicates absence of extranodal metastases; M+, presence of extranodal metastases at the time of diagnosis.
Staining assessment: ++, strong staining of all malignant cells; +, staining of most malignant cells; +/−, faint staining of a minority of malignant cells; −, absence of staining.
Figure W1. Detection of EBERs by in situ hybridization on tissue sections from three NPC xenografts (C666-1, C15, and C17). This
procedure was done using the INFORM-EBER kit from Ventana (Tucson, AZ). In all three xenografts, most nuclei are strongly positive
for EBER hybridization (original magnification, ×400).
Table W2. Summary of the Top 10 Genes Overexpressed in Both C15 and C17 NPC Xenografts, as Shown by Microarray Analysis of Transcription Using Confluent MRC5 Fibroblasts as a Reference
(Agilent Pangenomic Oligo-array Ref. G4110A).
Gene Symbols (HUGO Nomenclature) Common Designation of the Gene Product Chromosome Location Microarray Analysis of Transcription
(NPC Xenograft/MRC5, Fold Change)
C15/MRC5* C17/MRC5
TACSTD1 Tumor-associated calcium signal transducer 1 2p21 27.92 74.30
SCYA20 CCL20 chemokine 2q33-37 26.55 23.39
PCOLCE2 Procollagen C-endopeptidase enhancer 2 3q21-24 24.43 21.48
CSTA Cystatin A 3q21 64.57 70.59
FAT10 Ubiquitin D or diubiquitin 6p21 47 69
HLA-DRB5 6p21.3 17.87 18.45
HLA-DRA 6p21.3 16.33 24.21
HLA-DQB1 6p21.3 21.53 21.88
EPHX2 Cytosolic epoxide hydroxylase 8p21-p12 21.93 18.75
ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 9q21.13 20.28 29.99
BIRC3 c-IAP2 11q22 35.98 32.73
OCA2 Melanocyte-specific transporter 15q11.2-q12 32.36 44.88
PLA2G3 Secreted phospholipase A2, group III 22q11.2q13.2 16.14 27.73
*Human untransformed MRC5 fibroblasts were collected in a state of quiescence after 3 days of growth arrest resulting from cell confluence.
